Cidofovir dihydrate
(Synonyms: 西多福韦二水合物; GS 0504 dihydrate; HPMPC dihydrate; (S)-HPMPC dihydrate) 目录号 : GC13936
An antiviral agent and active metabolite of brincidofovir
Cas No.:149394-66-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.Target: CMV DNA polymeraseCidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir.Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Hol , and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions.
References:
[1]. Becker MN, et al. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol J. 2008 May 14;5:58.
[2]. Kazory A, et al. Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir. J Antimicrob Chemother. 2007 Jul;60(1):193-4. Epub 2007 May 11.
[3]. Segarra-Newnham M, et al. Use of cidofovir in progressive multifocal leukoencephalopathy. Ann Pharmacother. 2001 Jun;35(6):741-4.
| Cas No. | 149394-66-1 | SDF | |
| 别名 | 西多福韦二水合物; GS 0504 dihydrate; HPMPC dihydrate; (S)-HPMPC dihydrate | ||
| 化学名 | [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid;dihydrate | ||
| Canonical SMILES | C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O | ||
| 分子式 | C8H18N3O8P | 分子量 | 315.22 |
| 溶解度 | ≥ 34.6mg/mL in Water with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1724 mL | 15.8619 mL | 31.7239 mL |
| 5 mM | 0.6345 mL | 3.1724 mL | 6.3448 mL |
| 10 mM | 0.3172 mL | 1.5862 mL | 3.1724 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。